The FDA has authorized the Emergency use of REGEN-COV for the treatment of COVID-19

[Tupelomojo]

For those who don't know; The FDA has authorized the emergency use of REGEN-COV for the treatment of COVID-19 and the post-exposure prevention of COVID-19 under an Emergency Use Authorization (EUA).

REGEN-COV consists of two investigational medicines, casirivimab and imdevimab, given together as a single intravenous infusion (through a vein). You will receive one dose of REGEN-COV by intravenous infusion. The infusion will take 20 to 50 minutes or longer. Your healthcare provider will determine the duration of your infusion.

FACT SHEET FOR PATIENTS, PARENTS AND CAREGIVERS …@ regeneron.com/search?query=...

Stay Safe 😁

[lankisterguy Volunteer]

Thanks Tupelomojo,-

That is timely information.

-

Here a map showing where it is available:

Infusion Centers in USA that infuse Regen-COV- see interactive map at covid.infusioncenter.org/

-

Len

[Tupelomojo in reply to lankisterguy]

I second your link Lanki ------ covid.infusioncenter.org 👍‍ Thanks

[Cgolen99]

I was really happy to read this! I had my oncology visit last week and she indicated that if I tested positive I would get this. However, this says it is approved for "exposure" for folks like us. I may need to send her this article. Does anyone else send their oncologist articles or studies they read? I want to be prepared just in case! Thanks!

[Tupelomojo in reply to Cgolen99]

👍‍

[Palmetto]

It does not require infusion Can also be 4 shots in the U S

[Tupelomojo in reply to Palmetto]

Palmetto, please elaborate. Perhaps a link for the folks

👍

[Tupelomojo in reply to Palmetto]

Hi Palmetto,

I freed up some time, so I decided to get more detailed info on your comment myself.

The authorized dose for REGEN-COV for both treatment and as post-exposure prophylaxis is 600 mg of casirivimab and 600 mg of imdevimab administered together.

For treatment, intravenous infusion is strongly recommended; subcutaneous (under the skin) injection is authorized as an alternative route of administration when intravenous infusion is not feasible and would lead to delay in treatment.

For post-exposure prophylaxis, either intravenous infusion or subcutaneous injection is appropriate. For individuals who remain at high risk of exposure to another individual with SARS-CoV-2 for longer than 4 weeks, and who are not expected to mount an adequate immune response to full SARS-CoV-2 vaccination, following an initial dose of 600 mg of casirivimab and 600 mg of imdevimab, repeat doses of 300 mg of casirivimab and 300 mg of imdevimab once every 4 weeks are appropriate for the duration of ongoing exposure.

Link fda.gov/drugs/drug-safety-a...

Stay Safe 👍‍

[Cgolen99 in reply to Tupelomojo]

Thank you SO much for this!

[Tupelomojo in reply to Cgolen99]

Hi 99, I'm so glad that you liked it - have a great day